Voices

Estela Rodriguez Shared Insights on Day 1 of WCLC25

Estela Rodriguez/X

Sep 7, 2025, 04:42

Estela Rodriguez Shared Insights on Day 1 of WCLC25

Estela Rodriguez, Associate Director of Community Outreach and Co-Lead of Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center, shared a post on X:

“Day 1 of IASLC WCLC25 with a lot of new data to come out tomorrow morning at the Presidential Symposium on management of Biomarker-driven lung cancer:

FLAURA2 OS of Osimertinib +chemo in 1L EGFR
ACROSS2 Aumolertinib +chemo in 1L EGFR
HARMONI Ivonescimab + chemo post EGFR TKI
ARROS-1 Zidesamtinib post ROS1 TKI
ALCHEMIST Adjuvant Crizotinib for ALK+”

Yvonne Diaz, Director of Global Media Relations and Social Media at EY and Co-Founder of Oncogene Cancer Research, shared her post adding:

“On now at IASLC WCLC25.

Look forward to commenting on these important abstracts at today’s press conference. For patients, every new trial, every incremental step forward, means time, hope, and options for real people.”

More from WCLC25 on OncoDaily.

ACROSS2 ALCHEMIST ARROS-1 Aumolertinib cancer crizotinib Estela Rodriguez FLAURA2 HARMONi IASLC ivonescimab Lung cancer OncoDaily Oncogene Cancer Research Oncology osimertinib Sylvester Comprehensive Cancer Center WCLC25 Yvonne Diaz zidesamtinib

Aparna Parikh Has Been Named Program Director for the GI Medical Oncology Program at Mass General Brigham

Herbert Loong: Grateful for the Journey with ASCO International Affairs Committee

Unreleased Decision Letters From 2024–2025 Now Available - FDA

Servier and IDEAYA Biosciences Partner to Advance Darovasertib for Uveal Melanoma

FDA Grants Breakthrough Therapy Designation to Zongertinib (HERNEXEOS) for First-Line Treatment of HER2-Mutant Advanced NSCLC